Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pfizer ReEnters Poultry Vaccines
November 20, 2006
| A version of this story appeared in
Volume 84, Issue 47
Pfizer Animal Health has agreed to purchase Embrex, an agricultural biotechnology company, in a stock deal valued at $155 million. Embrex' lead product, Inovoject, is a technology to deliver poultry vaccine. "This acquisition represents an excellent opportunity to leverage Embrex' innovative technologies and for Pfizer to reenter the poultry business," says Juan Ramon Alaix, president of Pfizer Animal Health. The company flew the coop in 2000 when it sold its feed additives operations. Pfizer, which has been pursuing human vaccine acquisitions since 2004, purchased PowderMed, a supplier of vaccine delivery technology, in October.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X